{"DataElement":{"publicId":"11366165","version":"1","preferredName":"Therapeutic Procedure Pegaspargase And/Or Calaspargase Administered Indicator","preferredDefinition":"The indicator of whether pegaspargase and/or calaspargase was administered.","longName":"PEG_CALAS_ADMIN_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"11366164","version":"1","preferredName":"Therapeutic Procedure Pegaspargase And/Or Calaspargase Pegol-mknl Administered","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)_Used to indicate that either or both of two items or options may be valid._An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol-mknl L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation._The act of having given something (e.g., a medication or test).","longName":"2512834v1.00:11366163v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2512834","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B89860A-B9D6-3798-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11366163","version":"1","preferredName":"Pegaspargase And/Or Calaspargase Pegol-mknl Administered","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)_Used to indicate that either or both of two items or options may be valid._An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol-mknl L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation._The act of having given something (e.g., a medication or test).","longName":"C1200:C48928:C78198:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Calaspargase Pegol","conceptCode":"C78198","definition":"An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol, L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA360C10-F56F-46AB-E053-731AD00AD95A","latestVersionIndicator":"Yes","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA360C10-F570-46AB-E053-731AD00AD95A","latestVersionIndicator":"Yes","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-20","changeDescription":null,"administrativeNotes":"2022.10.20 Reviewed and released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"11366160","version":"1","preferredName":"Yes No Not Applicable Not Prescribed Indicator","preferredDefinition":"The affirmative response to a question._The non-affirmative response to a question._Determination of a value is not relevant in the current context._An indication that a material or agent was not prescribed as part of a treatment plan._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"11366160v1.00","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3382682","version":"1","preferredName":"No","longName":"3382682","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B99068EB-6AAA-AE1D-E040-BB89AD4362C9","latestVersionIndicator":"Yes","beginDate":"2012-02-22","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA3582DB-7127-30A7-E053-731AD00A7724","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2022-10-04","modifiedBy":"ONEDATA","dateModified":"2022-10-04","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA3582DB-7128-30A7-E053-731AD00A7724","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2022-10-04","modifiedBy":"ONEDATA","dateModified":"2022-10-04","deletedIndicator":"No"},{"value":"Not prescribed","valueDescription":null,"ValueMeaning":{"publicId":"11366161","version":"1","preferredName":"Not Prescribed","longName":"11366161v1.00","preferredDefinition":"An indication that a material or agent was not prescribed as part of a treatment plan.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Prescribed","conceptCode":"C188168","definition":"An indication that a material or agent was not prescribed as part of a treatment plan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA358D8C-C8B2-31CC-E053-731AD00A6097","latestVersionIndicator":"Yes","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA358D8C-C8B3-31CC-E053-731AD00A6097","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-04","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":null,"ValueMeaning":{"publicId":"7590024","version":"1","preferredName":"Not Applicable","longName":"7590024","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCB96B6E-DDC3-6924-E053-4EBD850AEF18","latestVersionIndicator":"Yes","beginDate":"2021-03-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2021-03-04","modifiedBy":"KUMMEROA","dateModified":"2023-11-29","changeDescription":null,"administrativeNotes":"7/8/22 added alt name of NA for CCTG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA35969B-A8A3-328C-E053-731AD00AE3F8","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"11366162","version":"1","preferredName":"Yes No Not Applicable Not Prescribed Indicator","preferredDefinition":"The affirmative response to a question._The non-affirmative response to a question._Determination of a value is not relevant in the current context._An indication that a material or agent was not prescribed as part of a treatment plan._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"11366162v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Not Prescribed","conceptCode":"C188168","definition":"An indication that a material or agent was not prescribed as part of a treatment plan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA35D1AC-5E23-409E-E053-731AD00ADB13","latestVersionIndicator":"Yes","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA3582E3-2D72-309A-E053-731AD00A8B64","latestVersionIndicator":"Yes","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeDescription":null,"administrativeNotes":"2022.10.4 Created for ticket request CADSR0001572. ak 2022.10.20 Reviewed and released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Was pegaspargase and/or calaspargase administered?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Did patient receive Pegaspargase/Calaspargase during this Reporting Period?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA3624E8-86B2-4968-E053-731AD00AEC45","latestVersionIndicator":"Yes","beginDate":"2022-10-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-10-04","modifiedBy":"KUMMEROA","dateModified":"2022-10-20","changeDescription":null,"administrativeNotes":"2022.10.4 Created for ticket request CADSR0001572. ak 2022.10.20 Reviewed and released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}